ORPHAZYME ENDORSES PATIENT ADVOCACY CONSENSUS GUIDELINES, HIGHLIGHTS IMPORTANCE OF COLLABORATION WITH PATIENT COMMUNITIES

Copenhagen, October 15, 2018 – Orphazyme A/S, a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announced the company’s endorsement of published guidelines to support interactions with rare disease patient advocacy organizations.

ORPHAZYME REPORTS ENCOURAGING ARIMOCLOMOL CLINICAL TRIAL TOP-LINE DATA IN NIEMANN-PICK DISEASE TYPE C (NPC)

Copenhagen, September 28, 2018 – Orphazyme A/S, a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announced encouraging top-line results for its clinical Phase II/III trial with orally administered arimoclomol for the treatment of patients with Niemann-Pick disease Type C (NPC).

ORPHAZYME TO PRESENT AT 25TH NPUK ANNUAL FAMILY CONFERENCE 2018

Copenhagen, September 20, 2018 – Orphazyme A/S, a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announced that Thomas Kirkegaard Jensen, Chief Scientific Officer at Orphazyme, will be presenting at the 25th NPUK Annual Family Conference 2018 in Wyboston, Bedfordshire, UK, on September 21-22, 2018.

ORPHAZYME TO PRESENT AT INVESTORDAGEN 2018

Copenhagen, September 18, 2018 – Orphazyme A/S, a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announced that Anders Hinsby, Chief Executive Officer at Orphazyme, will be presenting at Dansk Aktionærforening’s InvestorDagen in Copenhagen, Denmark, today, September 18, 2018 at 10.20 AM CET.

For free participation, please visit www.InvestorDagen.dk and use the code VIPOrphazyme2018.

ORPHAZYME TO PRESENT AT BIOCENTURY 25TH ANNUAL NEWSMAKERS IN THE BIOTECH INDUSTRY

Copenhagen, September 6, 2018 – Orphazyme A/S, a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announced that Anders Hinsby, Chief Executive Officer at Orphazyme, will be presenting at the BioCentury 25th Annual NewsMakers in the Biotech Industry in New York, USA on September 7, 2018 at 9.30 AM EDT.

ORPHAZYME INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FIRST HALF 2018 PRESENTATION

Copenhagen, August 22, 2018 – Orphazyme A/S, a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announced that the Company will be hosting an investor call at which Chief Executive Officer, Anders Hinsby, and Chief Financial Officer, Anders Vadsholt, will be presenting the Orphazyme Interim Condensed Consolidated Financial Statements First Half 2018. The presentation will be followed by a Q&A session.